Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists (NSAs), issued a correction on April 28, 2026, to its earlier press release regarding its partnership with TARA Mind. The correction removed references to Veterans Exploring Treatment Solutions from earlier paragraphs while reaffirming the collaboration’s alignment with a recent executive order aimed at advancing mental health treatments and clinical research participation.
The partnership is designed to support Phase 3 recruitment for Helus Pharma’s HLP003 program in major depressive disorder (MDD) and expand outreach in veteran communities. HLP003, a proprietary NSA, is currently in Phase 3 clinical development for the adjunctive treatment of MDD and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. The company also has HLP004, another proprietary NSA, in Phase 2 for generalized anxiety disorder, along with an extensive research portfolio of investigational NSAs.
Helus Pharma, the commercial operating name of Cybin Inc., founded in 2019, focuses on developing synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. These NSAs aim to address the large unmet need for people suffering from depression, anxiety, and other mental health conditions. With class-leading data, the company intends to improve the treatment landscape by introducing NSAs that provide durable improvements in mental health.
The correction to the partnership announcement is significant as it ensures accuracy in public disclosures, which is critical for investor confidence and regulatory compliance. The reaffirmed alignment with the executive order underscores the importance of public-private collaborations in advancing mental health treatments, particularly for veteran communities who often face unique challenges in accessing effective care.
The partnership with TARA Mind is expected to accelerate recruitment for the Phase 3 trial of HLP003, potentially bringing a new treatment option to patients with MDD sooner. MDD affects millions worldwide, and the need for effective adjunctive therapies remains high. The Breakthrough Therapy Designation from the FDA highlights the potential of HLP003 to offer meaningful improvements over existing treatments.
Helus Pharma operates in Canada, the United States, the United Kingdom, and Ireland. For company updates, visit www.helus.com or follow the team on social media. The full press release is available at https://ibn.fm/re8HL.
Investors and stakeholders are encouraged to review the corrected release and the latest news on HELP at the company’s newsroom: https://ibn.fm/HELP.
